Blood samples from coronavirus vaccine trials are handled inside the Jenner Institute in Oxford, England on June 25.
Moderna said the added investment was justified by its decision, in conjunction with the government, to “significantly” expand a Phase Three clinical trial of a candidate vaccine to include 30,000 participants. The US has suffered more than 146,000 coronavirus deaths, leading the world in that grim category, even as the number of new cases has continued to surge.
With laboratories around the world in a furious race to develop a first effective vaccine, Moderna seems to hold the lead as it enters a final round of clinical trials — a decisive step in determining whether a vaccine is both effective and safe.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: